


Study assesses NIH contribution to clinical development of new drugs

July 14 2023

NIH and industry investments in bringing new drugs to market



References: Cleary et al (2023), JAMA Health Forum and Zhou et al (2023), JAMA Health Forum



Characteristics of NIH and industry investments in pharmaceutical innovation.
Credit: Bentley University

The U.S. National Institutes of Health (NIH) contributed \$8.1 billion in project funding for phased clinical trials involving drugs approved by the

FDA from 2010–2019, according to a new study from Bentley University's Center for Integration of Science and Industry.

The study, published in *JAMA Health Forum*, shows that NIH funding for clinical trials represents 12 thousand publications describing phased [clinical trials](#) involving 240 of 387 (62%) approved drugs. Average NIH spending was \$33.8 million per approved drug and was significantly lower than reported industry spending.

Overall, NIH spending represented ~10% of reported industry spending including ~25% of phase 1 costs, ~22% of phase 2 costs, and ~4% of phase 3 costs. More than 90% of NIH funding came through mechanisms designed to advance the practice of translational science or [support programs](#) or centers that provide clinical research capabilities, patient networks or consortia, or training in clinical, translational, or regulatory science (including Clinical Translational Science Awards). Only 3.3% of the total NIH funding was provided through mechanisms that support investigator-initiated research.

Dr. Edward Zhou was the lead author of this work along with Dr. Matthew Jackson and Dr. Ledley.

More information: Spending on Phased Clinical Development of Approved Drugs by the US National Institutes of Health Compared with Industry, *JAMA Health Forum* (2023). [DOI: 10.1001/jamahealthforum.2023.1921](#) , [jamanetwork.com/journals/jama- ... ealthforum.2023.1921](#)

Provided by Bentley University

Citation: Study assesses NIH contribution to clinical development of new drugs (2023, July 14)

retrieved 2 May 2024 from

<https://medicalxpress.com/news/2023-07-nih-contribution-clinical-drugs.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.